Introduction
In recent years, the association between PCa risk and some single-nucleotide polymorphisms of VDR gene has become the focus of research attention. 9 We also conducted a meta-analysis on Taq I and Fok I polymorphisms and their relationships with PCa risk. 7 Bsm I polymorphism (rs1544410) is one of the most frequently researched variants. It is a restriction site located in intron 8 of VDR gene, which does not affect the amino acid sequence during VDR protein expression. 10 However, mutations in the intron region might be able to lower the stability of mRNA and affect the mRNA levels. Numerous research has revealed that Bsm I mutation might play a significant role in the development or progression of PCa. [11] [12] [13] [14] However, some other studies do not support this association. [15] [16] [17] [18] These results are inconsistent and worth further exploration. In addition, previous meta-analyses 10, [19] [20] [21] [22] seemed to be out of date due to availability of new data. 3, 9, 14, 23, 24 Therefore, we performed a new meta-analysis with the aim of obtaining more accurate and updated results.
Methods

Literature retrieval strategy
PubMed, Embase, and China National Knowledge Infrastructure (CNKI) electronic databases were searched for eligible studies published till December 2017. The terms "VDR/ vitamin D receptor", "prostate cancer/tumor/carcinoma", and "polymorphism/mutation/variant" were used for searching titles or abstracts. 
Study selection
Candidate studies were evaluated by two authors independently (Lei Wang and Jian Liu) for the following inclusion criteria: (1) studies in nonfamilial case-control or nested case-control design conducted on human beings; (2) studies that assessed the relationship between Bsm I polymorphism and risk or progression of PCa; (3) studies in which the distribution frequency of genotype and allelic profile of participants could be acquired or calculated; (4) studies in which no significant difference was reported between cases and controls in the aspect of baseline characters; (5) studies that scored more than 5 points on the Newcastle-Ottawa Scale (NOS).
Data extraction
Two investigators (Lei Wang and Jian Liu) collected the following information independently: first author's name, publication year, population information, genotyping methods, the number of participants, genotype and allelic profile, as well as the source of controls. Cases and controls were classified into different subgroups by ethnicity, source of controls, and genotyping method, respectively. The subjects were also divided into group with Gleason score <7 and group with Gleason score ≥7 by pathological grade, and localized group and aggressive group by clinical stages, respectively. Any controversial content was discussed and evaluated by a third reviewer (Yansheng Zhao) to reach an agreement on all the items.
Statistical analyses
The heterogeneity was evaluated by using c 2 -test based on Cochran's Q-test and I 2 statistics. If I 2 >50% and p<0.05, the heterogeneity between studies was significant and the random-effects model was used to combine the values from single studies; 25 otherwise, in the absence of heterogeneity, the fixed-effects model was chosen. The pooled odds ratios (ORs), together with 95% confidence intervals (CIs), were calculated to assess the strength of the relationship. For each outcome, we also conducted subgroup analyses by ethnicity, the source of controls, genotyping method, and clinical stages. p-values were two-sided, and p<0.05 was considered statistically significant. All analyses were done using the STATA package version 12.0 (Stata Corp, College Station, TX, USA).
Results
Characteristics of studies
A total of 87 studies were identified to be potentially related to the topic through our search strategy. Following our inclusion criteria, 27 studies 3, 9, [11] [12] [13] [14] [15] [16] [17] 23, 24, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] published between the years 1998 and 2017 were finally included to evaluate the association ( Figure 1 ). As shown in Table 1 , out of the 27 studies, 25 explored the relationship of PCa risk with Bsm I, and nine were about the association between PCa progression and Bsm I. The number of participants in the case group and control group varied from 28 to 1,034, and 30 to 1,566, respectively. For all studies, except five, the genotype distribution frequency of Bsm I polymorphism in the control groups conformed to the HWE. All the studies scored more than 5 on the NOS, and were considered to be of high quality ( Table 2 ). In the subgroup analyses conducted for a more detailed evaluation of the relationship, the results did not reveal any association by different ethnicities (Table 3) , different genotyping methods (Table 4) , or different HWE statuses of control groups (results not shown).
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Pooled results in terms of Bsm I polymorphism with PCa progression
Stratified analyses, according to the clinical stages and Gleason score of patients, were also performed. As shown in Table 6 , the pooled results for the patients with Gleason score <7 and Gleason score ≥7 did not reveal any relationship between the Bsm I variant and PCa risk in various genetic models compared to controls. Similarly, the subgroup of PCa cases with localized stage and aggressive stage showed no association.
In the inter-patient comparisons by different clinical stages and Gleason score statuses, a weak influence of Bsm I polymorphism on PCa progression was detected in patients with Gleason score ≥7 compared to the group with Gleason score <7 (BB/Bb vs. bb: OR=1.176, 95% CI=1.008-1.373, p=0.04). However, no effect of Bsm I polymorphism on the clinical stages was detected ( Figure 4 and Table 6 ).
Publication bias and sensitivity analysis
The funnel plots for publication bias analysis did not show any significant asymmetry in the overall analysis ( Figure 5 ). 
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Moreover, Begg's and Egger's tests also revealed no publication bias in overall analysis as well as subgroup analyses (Tables 2-6 ). Sensitivity analysis for the positive results suggested that no obvious change in the pooled results was detected by omitting each individual study for the subgroup analysis of BPH controls, while the results were unstable in the comparison of PCa cases in terms of Gleason scores ( Figure 6 ).
Discussion
Polymorphisms of VDR gene and their relationships with PCa susceptibility have drawn a lot of attention in recent years. Bsm I polymorphism is one of the "star biomarkers". Even though Bsm I polymorphism is located in the noncoding regions of VDR gene, it is frequently considered to be associated with PCa risk by numerous studies. 9, 11, 12, 39 Meanwhile, some studies support the opposite conclusion. 15, 16, 30, 34 Five meta-analyses conducted by Yin et al, 19 Zhang et al, 20 Guo et al, 21 Xu et al, 22 and Liu et al, 10 including 14, 19, 19, 15, and 6 primary studies, respectively, also yielded conflicting results. Moreover, some new data were reported. 3, 9, 14, 23, 24 Therefore, a new meta-analysis is necessary to clarify this issue. In the present study, data of 27 independent studies including 9,993 cases and 9,345 controls, which is higher compared to the previous meta-analyses, were pooled. Therefore, our updated results will be more convincing and stringent.
According to our results, no association between PCa risk and Bsm I polymorphism was detected in the overall population, which was similar to the results reported by Guo et al, 21 Liu et al, 10 and Xu et al, 22 but different from the other two meta-analyses.
19,20 As we mentioned above, the results of previous meta-analyses might be suspect due to outdated data or inclusion of incomplete studies. Ethnicity might be an important biological factor for the genetic difference. 42 The genotype frequency distribution of Bsm I was found to be different between Asians, Caucasians and Africans, but in each subgroup by ethnicity, no association was found. In addition, subgroup analyses by the genotyping method and HWE status both revealed no influence of Bsm I on PCa risk, suggesting that these two variables would not change the negative result of the overall analysis either.
An interesting finding was that according to the results of the subgroup analysis by different sources of controls, Bsm I mutation increased the risk of PCa in BPH controls in the heterozygote model, recessive model, and allele model. Moreover, this result was proved to be robust by sensitivity analysis, and the heterogeneity was found to be acceptable as well. Based on this result, for individuals with BPH, the bb genotype or b might increase the risk of PCa, however, this result was suspicious and difficult to explain. Age was reported to be a risk factor for the relationship between Bsm I mutation and PCa risk. 26, 35 We intended to perform a subgroup meta-analysis by age, but the age classification in the included studies was too ambiguous to be pooled.
Similar to overall analysis, subgroup analyses by clinical stage and Gleason score revealed no relationship between 
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Association between Bsm I polymorphism and PCa risk: a meta-analysis PCa risk and Bsm I. Moreover, we conducted inter-patient analysis to assess the relationship of Bsm I polymorphism with PCa progression by comparing cases with aggressive stage and Gleason score ≥7 to cases with localized stage and Gleason score <7, respectively. Almost all the results were negative, except for the comparison between cases with Gleason score ≥7 and <7 in the recessive model. However, the only positive result was not stable in sensitivity analysis. Therefore, we have ignored the weak relationship. Regrettably, we failed to perform a subgroup analysis by vitamin D intake, because only two primary studies have a detailed description of the effect of plasma vitamin D levels on the association between Bsm I and PCa risk. Ma et al reported that in patients with low levels of 25-D, which is one of the vitamin D metabolites, the PCa risk would be significantly increased by carrying bb genotype. 33 Meanwhile, in the group with high levels of 25-D, the relationship was not significant. Similar results were reported by Ahn et al in 2009 . 18 These studies suggest that plasma levels of 25-D might influence our pooled result, and a stratified analysis by vitamin D intake or 25-D levels is warranted in the future.
Significant heterogeneity between studies was detected in both overall analysis and subgroup analyses under multiple comparison models. We noted that the BB genotype in the Asian group was quite rare but very commonly detected in Caucasians and Africans. It may contribute to this heterogeneity. However, no obvious publication bias was found and the sensitivity analysis supported the stability of our results.
Overall, the present analysis was credible and statistically valid for the studied population. However, some limitations of our meta-analysis should be acknowledged. First of all, some reports with a small number of cases and controls were included in our analysis, which increases the statistical power but introduces potential bias and heterogeneity as well. Second, our pooled outcomes were based on the initial results of the included studies, which were not adjusted by patient characteristics and other 
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Overall Figure 5 Begg's funnel plots to examine publication bias for reported comparisons of VDR gene Bsm I polymorphism for the homozygote model in the (A) overall analysis and (B) the subgroup analysis of BPH controls. Abbreviations: BPH, benign prostatic hyperplasia; OR, odds ratio. Ezzai et al, 2014 24 Habuchi et al, 2000 12 Nam et al, 2003 35 Nunes et al, 2016 14 Oh 
